NCT00171106已完成4 期
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Change in baseline exercise test after 15-42 days and 14 weeks
研究概览
简要总结
This study will test the effects of valsartan versus placebo on exercise tolerance in patients with symptoms of heart failure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic diastolic heart failure
- •Breathlessness with physical exertion
排除标准
- •Uncontrolled hypertension
- •Asthma, COPD, or abnormal lung function
- •History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- •Liver, kidney, or pancreas disease
- •Allergy to valsartan
- •Other protocol-defined exclusion criteria may apply
结局指标
主要结局
Change in baseline exercise test after 15-42 days and 14 weeks
次要结局
- Borg score of breathlessness
- Quality of life assessment at baseline and after 14 weeks
- Exercise test blood pressure
- 6-minute walk test at baseline and after 14 weeks
- Oxygen consumption during the exercise test
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal WomenHypertensionNCT00171132Novartis64
已完成
4 期
Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes MellitusHypertensionType 2 Diabetes MellitusCoronary Artery DiseaseNCT00982358Charite University, Berlin, Germany121
撤回
4 期
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes MellitusCoronary Artery DiseaseAngina PectorisNCT01334203Gilead Sciences
已完成
2 期
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolChronic Obstructive Pulmonary DiseaseNCT00531050Novartis27
招募中
不适用
Study on Heart Failure with Preserved Ejection Fraction with Qishen GranulesHeart Failure with Preserved Ejection FractionNCT06377761Guangdong Provincial Hospital of Traditional Chinese Medicine80